BREAKING: Federal Bill Introduced to Strip COVID-19 “Vaccine” Manufacturers of Liability Protection

Key Takeaways

• LIABLE Act removes PREP Act immunity
• Allows retroactive lawsuits against COVID‑19 vaccine manufacturers
• Potentially billions in claims from millions of injured Americans
• Pfizer and Moderna could face bankruptcy risk
• CICP has paid only a few claims historically

Summary

Representative Chip Roy introduced the Let Injured Americans Be Legally Empowered (LIABLE) Act, which would strip COVID‑19 vaccine manufacturers of the federal immunity granted under the PREP Act. The bill would permit civil lawsuits against Pfizer, Moderna and others, even for vaccinations administered before the legislation’s passage. It also allows claimants to pursue litigation after filing in the Countermeasures Injury Compensation Program, effectively opening a retroactive legal pathway. If enacted, the measure could trigger millions of suits and threaten the financial stability of major vaccine producers.

Pulse Analysis

During the COVID‑19 pandemic, vaccines were classified as medical countermeasures, invoking the PREP Act’s broad liability protections. This shield diverted injury claims to the Countermeasures Injury Compensation Program, a little‑known federal fund that has compensated only a fraction of petitioners. By insulating manufacturers from civil suits, the government aimed to accelerate vaccine rollout, but it also left many injured individuals without a clear path to restitution.

The newly introduced LIABLE Act seeks to overturn that framework. Sponsored by Rep. Chip Roy and co‑sponsored by a cohort of libertarian‑leaning lawmakers, the bill would eliminate all federal statutes granting immunity to COVID‑19 vaccine producers and apply retroactively. It explicitly permits plaintiffs to sue even after filing a CICP claim, opening the door for potentially millions of lawsuits spanning the entire pandemic period. The legislation reflects growing political pressure from constituents who feel the existing compensation system is inadequate.

If passed, the legal exposure could be unprecedented. Liability estimates run into the tens of billions of dollars, a scale that could strain or even bankrupt firms like Pfizer and Moderna, reshaping the pharmaceutical industry's risk calculus. Such a shift may deter rapid vaccine development in future health crises, as companies weigh the prospect of unlimited civil suits against public‑health imperatives. Stakeholders—from investors to policymakers—must weigh the balance between accountability for vaccine injuries and preserving the incentives that enable swift medical innovation.